

In the Claims

1-70 (canceled).

71 (new). A method of treating an obesity comprising the administration of a composition comprising administering a composition comprising a soluble T-cadherin polypeptide to an obese individual, wherein said soluble T-cadherin polypeptide:

- a) consists of amino acids 23-692 of SEQ ID NO: 1;
- b) comprises SEQ ID NO: 1, wherein the glycosylphosphatidylinositol (GPI)-anchor site at position 693 of SEQ ID NO: 1 has been mutated;
- c) comprises a heterologous sequence fused to a polypeptide that consists of amino acids 23 to 692 of SEQ ID NO: 1; or
- d) comprises a polypeptide that comprises SEQ ID NO: 1, wherein the glycosylphosphatidylinositol (GPI)-anchor site has been mutated fused to a heterologous sequence.

72 (new). The method of claim 71, wherein said soluble T-cadherin consists of amino acids 23 to 692 of SEQ ID NO: 1.

73 (new). The method of claim 72, wherein said soluble T-cadherin comprises SEQ ID NO: 1, wherein the glycosylphosphatidylinositol (GPI)-anchor site has been mutated.

74 (new). The method of claim 72, wherein said soluble T-cadherin comprises a heterologous sequence fused to a polypeptide that consists of amino acids 23 to 692 of SEQ ID NO: 1.

75 (new). The method of claim 72, wherein said soluble T-cadherin comprises a polypeptide that comprises SEQ ID NO: 1, wherein the glycosylphosphatidylinositol (GPI)-anchor site has been mutated fused to a heterologous sequence.